TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9013351

Group type: EXPERIMENTAL
Intervention: HIV-seropositive patients with abdominal tuberculosis
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: HIV-seronegative patients with abdominal tuberculosis
Number of subjects: 108

Group type: COMPARATOR
Intervention: Patients with pulmonary tuberculosis
Number of subjects: 108

Group type: COMPARATOR
Intervention: Volunteer blood donors
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Patients with abdominal tuberculosis (both HIV-seropositive and HIV-seronegative)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: HIV-seropositive patients
Number of subjects: 108
Study: 7886411

Group type: EXPERIMENTAL
Intervention: Lignocaine 400 mg (40 ml of a 1% solution) instilled for 1 hour in Group A patients (n = 9)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Lignocaine instilled for 2 hours in Group B patients (n = 2)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Intravesical application of lignocaine
Number of subjects: 11
Study: 3164163

Group type: EXPERIMENTAL
Intervention: Physical training program for the stomatognathic system (E groups)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (C groups)
Number of subjects: 60
Study: 31942918

Group type: EXPERIMENTAL
Intervention: Physical Activity and Sleep Health (PAS)
Number of subjects: 275

Group type: EXPERIMENTAL
Intervention: Sleep Health Only (SO)
Number of subjects: 275

Group type: COMPARATOR
Intervention: Wait-list Control (CON)
Number of subjects: 275
Study: 29290184

Group type: EXPERIMENTAL
Intervention: Intense Pulse Light Therapy (IPL) and Triple Combination Cream (TCC)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Intense Pulse Light Therapy (IPL)
Number of subjects: 96
Study: 28349908

Group type: EXPERIMENTAL
Intervention: 0.5% NaF‐impregnated miswak
Number of subjects: 15

Group type: COMPARATOR
Intervention: Toothbrush with 1450 ppm fluoride toothpaste
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nonfluoridated miswak
Number of subjects: 15

Group type: COMPARATOR
Intervention: Toothbrush with nonfluoride toothpaste
Number of subjects: 15
Study: 26386788

Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Number of subjects: 1530

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 1530
Study: 24123600

Group type: EXPERIMENTAL
Intervention: Imatinib 400 mg/d
Number of subjects: 344

Group type: COMPARATOR
Intervention: Imatinib 600 mg/d
Number of subjects: 344
Study: 20851499

Group type: EXPERIMENTAL
Intervention: ME-609 (5% acyclovir and 1% hydrocortisone)
Number of subjects: 2437

Group type: COMPARATOR
Intervention: 5% acyclovir in ME-609 vehicle
Number of subjects: 2437

Group type: COMPARATOR
Intervention: Placebo (ME-609 vehicle)
Number of subjects: 2437

Group type: EXPERIMENTAL
Intervention: ME-609
Number of subjects: 2437
Study: 18359363

Group type: EXPERIMENTAL
Intervention: OPMI TwinEr:YAG laser
Number of subjects: 152

Group type: COMPARATOR
Intervention: Manual microperforators
Number of subjects: 152
Study: 16284710

Group type: EXPERIMENTAL
Intervention: Microtip transducers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: External water pressure transducer catheters
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microtip and water pressure transducer combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Microtip and water pressure transducers
Number of subjects: 0
Study: 14674504

Group type: COMPARATOR
Intervention: Group 1: conventional mode (Elipar Highlight)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group 2: step mode (Elipar Highlight)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group 3: ramp mode (Elipar Trilight)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Group 4: pulse mode (VIP)
Number of subjects: 40
Study: 11306153

Group type: EXPERIMENTAL
Intervention: Four-drug combination with protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) plus nucleoside analogue (NRTI) drugs
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Three-drug combinations (PI followed by NNRTI or NNRTI followed by PI)
Number of subjects: 980

Group type: EXPERIMENTAL
Intervention: Dual NRTI combinations (zidovudine plus lamivudine followed by didanosine plus stavudine or vice versa)
Number of subjects: 980

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 980
Study: 9736326

Group type: EXPERIMENTAL
Intervention: Bromocriptine (BRC) 2.5 mg daily
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study: 8279598

Group type: EXPERIMENTAL
Intervention: Booklet
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: Videotape
Number of subjects: 1100

Group type: COMPARATOR
Intervention: No intervention (Control)
Number of subjects: 1100
Study: 2741861

Group type: EXPERIMENTAL
Intervention: Furosemide (1 mg/kg IV every 24 hours)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ethacrynic acid (1 mg/kg IV every 24 hours)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Furosemide and ethacrynic acid (alternating doses)
Number of subjects: 10
Study: 165796

Group type: EXPERIMENTAL
Intervention: REM sleep reduction (by awakenings) for three weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (non-REM sleep awakenings)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride treatment
Number of subjects: 52
Study: 30849175

Group type: EXPERIMENTAL
Intervention: MMR-RIT (1 of 3 production lots)
Number of subjects: 5003

Group type: COMPARATOR
Intervention: MMR II
Number of subjects: 5003
Study: 30946919

Group type: EXPERIMENTAL
Intervention: Competitive leaderboard during intervention phase
Number of subjects: 919

Group type: COMPARATOR
Intervention: Control phase (no leaderboard)
Number of subjects: 919
Study: 28143599

Group type: EXPERIMENTAL
Intervention: Kiwi OmniCup® ventouse delivery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metal cup ventouse delivery
Number of subjects: 0
Study: 25582412

Group type: EXPERIMENTAL
Intervention: Dry needling in an MTrP in the lower trapezius muscle
Number of subjects: 72

Group type: COMPARATOR
Intervention: Dry needling in the lower trapezius muscle but not at an MTrP
Number of subjects: 72
Study: 22608271

Group type: EXPERIMENTAL
Intervention: Interventional cardiologists (ICs)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Protective lead glasses usage
Number of subjects: 106

Group type: COMPARATOR
Intervention: Unexposed control group (non-medical workers)
Number of subjects: 106
Study: 22008766

Group type: EXPERIMENTAL
Intervention: Isoniazid preventive therapy (IPT) for 6 months
Number of subjects: 558

Group type: COMPARATOR
Intervention: No isoniazid preventive therapy (non-completers)
Number of subjects: 558
Study: 18467083

Group type: EXPERIMENTAL
Intervention: 40mg astaxanthin
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: 16mg astaxanthin
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 17048421

Group type: EXPERIMENTAL
Intervention: 0.5% isobaric levobupivacaine (n = 35)
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.5% hyperbaric bupivacaine (n = 35)
Number of subjects: 70
Study: 14592559

Group type: EXPERIMENTAL
Intervention: Allele A455 carriers (HT smokers)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 4G allele carriers (4G/4G homozygotes in HT patients)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 4G/4G smokers
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 4G/4G genotype in smokers
Number of subjects: 90

Group type: COMPARATOR
Intervention: HT patients (general)
Number of subjects: 90
Study: 11071403

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 100

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 100
Study: 9169311

Group type: EXPERIMENTAL
Intervention: Reboxetine (NARI)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 549

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 549
Study: 1439274

Group type: EXPERIMENTAL
Intervention: Bacampicillin hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 30795794

Group type: EXPERIMENTAL
Intervention: Alpha power-maximisation anaesthesia titration strategy during maintenance phase of anaesthesia
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Early cessation of volatile anaesthesia and emergence from an intravenous infusion of propofol during emergence phase of anaesthesia
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard care avoiding suppression patterns in the EEG during maintenance phase of anaesthesia
Number of subjects: 600

Group type: COMPARATOR
Intervention: Standard emergence from volatile anaesthesia only during emergence phase of anaesthesia
Number of subjects: 600
Study: 29429537

Group type: EXPERIMENTAL
Intervention: Beverage containing 20 g of soluble fiber dextrin (SFD)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Beverage containing 0 g of soluble fiber dextrin (control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Beverage containing 10 g of soluble fiber dextrin (SFD)
Number of subjects: 41
Study: 25307063

Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography (LDCT)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Control (chest X-ray or usual care)
Number of subjects: 9
Study: 24072776

Group type: EXPERIMENTAL
Intervention: Bevacizumab therapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: MASS criteria evaluation after therapy
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Baseline serum LDH levels
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Combination of baseline serum LDH levels and MASS criteria evaluation
Number of subjects: 44
Study: 22855276

Group type: EXPERIMENTAL
Intervention: N(G)-nitro-l-arginine methyl ester (l-NMMA)
Number of subjects: 37
Study: 20199883

Group type: COMPARATOR
Intervention: Body composition evaluation using standard anthropometric procedures and CT of the abdomen and mid-femur level.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Circulating lipids measurement, oral glucose tolerance test (OGTT), and hormonal screening including GH secretory capacity (GHRH/arginine test).
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Assessment of visceral to subcutaneous abdominal fat ratio.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Correlation analysis of visceral abdominal fat fraction with subcutaneous fat, BMI, and peak GH-response.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Thigh muscle volume assessment.
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Sex-steroid replacement therapy.
Number of subjects: 46

Group type: COMPARATOR
Intervention: Comparison of body composition in PWS adults to non-PWS GHD adults.
Number of subjects: 46
Study: 18035131

Group type: EXPERIMENTAL
Intervention: dDAVP treatment
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 15569865

Group type: EXPERIMENTAL
Intervention: rtPA
Number of subjects: 2178

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2178
Study: 11890429

Group type: EXPERIMENTAL
Intervention: Real acupuncture treatment with needles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Simulated acupuncture using a toothpick in a guidetube
Number of subjects: 0
Study: 10396792

Group type: EXPERIMENTAL
Intervention: Intensive family‐focused interventions with methadone treated parents (33 sessions of family training combined with 9 months of home‐based case management)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Control condition (no supplemental services)
Number of subjects: 144
Study: 8847017

Group type: EXPERIMENTAL
Intervention: Locoregional immunostimulation and locoregional chemotherapy (Proleukin and Imukin infusion for 10 days, followed by locoregional chemotherapy 15 days later)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Laparotomy with palliative gastric or biliary bypass (control group)
Number of subjects: 66
Study: 1904189

Group type: EXPERIMENTAL
Intervention: Intravenous tissue plasminogen activator
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: History of prior infarction
Number of subjects: 222

Group type: COMPARATOR
Intervention: Invasive versus conservative treatment strategies
Number of subjects: 222

Group type: COMPARATOR
Intervention: Early versus delayed beta-blocker therapy
Number of subjects: 222
Study: 7020746

Group type: EXPERIMENTAL
Intervention: Oral diethylcarbamazine (DEC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Topical diethylcarbamazine (DEC) lotion
Number of subjects: 20
Study: 31412059

Group type: EXPERIMENTAL
Intervention: Using a decision aid (catalyst)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no catalyst)
Number of subjects: 0
Study: 28073858

Group type: EXPERIMENTAL
Intervention: Fractional-dose inactivated poliovirus vaccine (fIPV) administered intradermally on days 0 and 28
Number of subjects: 534

Group type: COMPARATOR
Intervention: Full-dose inactivated poliovirus vaccine (IPV) administered intramuscularly on days 0 and 28
Number of subjects: 534

Group type: EXPERIMENTAL
Intervention: Both fIPV and IPV
Number of subjects: 534
Study: 24975432

Group type: EXPERIMENTAL
Intervention: Oral morphine as first-line treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oral oxycodone as first-line treatment
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oral morphine as second-line treatment after switching
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oral oxycodone as second-line treatment after switching
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both opioids available (per-protocol analysis)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Adverse reactions to oral morphine
Number of subjects: 200

Group type: COMPARATOR
Intervention: Adverse reactions to oral oxycodone
Number of subjects: 200
Study: 23171815

Group type: EXPERIMENTAL
Intervention: Exercise augmentation with 16 kilocalories per kilogram of body weight per week (KKW) for 12 weeks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise augmentation with 4 KKW for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitor (SSRI) augmentation
Number of subjects: 0
Study: 20970246

Group type: EXPERIMENTAL
Intervention: Trained dogs sniffing urine samples from patients with prostate cancer
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control urine samples from patients with negative biopsies
Number of subjects: 66
Study: 19519257

Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) applied to the hip area
Number of subjects: 23

Group type: COMPARATOR
Intervention: Methylphenidate transdermal system (MTS) applied to the scapular area
Number of subjects: 23
Study: 18269868

Group type: EXPERIMENTAL
Intervention: Insulin glargine plus glimepiride 3 mg
Number of subjects: 80

Group type: COMPARATOR
Intervention: Premixed 30 R insulin (70/30) twice‐daily plus glimepiride 3 mg
Number of subjects: 80
Study: 15287454

Group type: EXPERIMENTAL
Intervention: Cerebral perfusion pressure (CPP) targeted therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Intracranial pressure (ICP) targeted therapy
Number of subjects: 17
Study: 11241545

Group type: EXPERIMENTAL
Intervention: Video intervention group
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2000
Study: 9439559

Group type: EXPERIMENTAL
Intervention: Healthy-living advice and sulfonylurea therapy
Number of subjects: 1580
Study: 8177056

Group type: EXPERIMENTAL
Intervention: Dieting with exercise (running)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Dieting without exercise
Number of subjects: 116

Group type: COMPARATOR
Intervention: Control (sedentary)
Number of subjects: 116
Study: 3067699

Group type: EXPERIMENTAL
Intervention: Chlorambucil with cisplatin
Number of subjects: 283

Group type: COMPARATOR
Intervention: Chlorambucil without cisplatin
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Surgical reexploration in patients with apparent remission at 12 months
Number of subjects: 283

Group type: COMPARATOR
Intervention: Patients not subjected to surgical reexploration
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Surgical reexploration in patients with responding and probably resectable residual disease at 12 months
Number of subjects: 283
Study: 31448832

Group type: COMPARATOR
Intervention: 1.2% SMV gel and covering the defect with occlusive membrane (OM)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1.2% SMV gel and covering the defect with perforated barrier membranes (PBM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 24% EDTA root surface etching, 1.2% SMV gel, and defect coverage with occlusive membrane (eOM)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 24% EDTA root surface etching, 1.2% SMV gel, and defect coverage with perforated barrier membranes (ePBM)
Number of subjects: 40
Study: 30923972

Group type: EXPERIMENTAL
Intervention: (R)-(-)-1-octen-3-ol
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: (S)-(+) -1-octen-3-ol
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 4
Study: 28273487

Group type: EXPERIMENTAL
Intervention: Intervention group (specific intervention details not available)
Number of subjects: 0
Study: 25404537

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 229

Group type: COMPARATOR
Intervention: 5-HT3 receptor antagonist
Number of subjects: 229
Study: 23422652

Group type: EXPERIMENTAL
Intervention: Daily G-CSF administration
Number of subjects: 47

Group type: COMPARATOR
Intervention: Every other day G-CSF administration
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: G-CSF administration
Number of subjects: 47
Study: 22044774

Group type: EXPERIMENTAL
Intervention: Sodium perborate (Corega Tabs) for 5 min once a day for 6 months
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chlorhexidine digluconate 2% for 5 min once a day for 6 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group - brushing with coconut soap and soft toothbrush
Number of subjects: 45
Study: 19796736

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 7200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7200

Group type: COMPARATOR
Intervention: Pravastatin 40 mg/day
Number of subjects: 7200

Group type: EXPERIMENTAL
Intervention: Composite endpoint of death, myocardial infarction, and rehospitalization for ACS
Number of subjects: 7200
Study: 17029276

Group type: EXPERIMENTAL
Intervention: Low-dose interferon-alpha-2b (IFN1) at a dose of 0.5 million units (MU) given subcutaneously twice daily
Number of subjects: 118

Group type: COMPARATOR
Intervention: Intermediate-dose interferon-alpha-2b (IFN5) at a dose of 5 MU given subcutaneously daily
Number of subjects: 118
Study: 14990561

Group type: EXPERIMENTAL
Intervention: High-dose phase (HP) after 4 months of OC use at 45% Vo(2 peak)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inactive phase (IP) after 4 months of OC use at 45% Vo(2 peak)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline (BOC) before OC use at 45% Vo(2 peak)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: High-dose phase (HP) after 4 months of OC use at 65% Vo(2 peak)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Inactive phase (IP) after 4 months of OC use at 65% Vo(2 peak)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Baseline (BOC) before OC use at 65% Vo(2 peak)
Number of subjects: 8
Study: 11412730

Group type: EXPERIMENTAL
Intervention: Remifentanil
Number of subjects: 90

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 90
Study: 9359440

Group type: EXPERIMENTAL
Intervention: External cephalic version (ECV) with tocolysis and vibroacoustic stimulation
Number of subjects: 478

Group type: COMPARATOR
Intervention: Control group (ECV not attempted)
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Successful version group
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Unsuccessful version group
Number of subjects: 478
Study: 8504632

Group type: EXPERIMENTAL
Intervention: L-Dihydroxyphenylalanine infusion (0.33 micrograms min‐1 kg‐1)
Number of subjects: 12
Study: 3308617

Group type: EXPERIMENTAL
Intervention: Vidarabine (15 mg/kg/day for 7 days then 7.5 mg/kg/day for 14 days)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vidarabine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vidarabine (second course)
Number of subjects: 30
Study: 31350928

Group type: EXPERIMENTAL
Intervention: Long screw group (LSG) with 4 mm TJD
Number of subjects: 20

Group type: COMPARATOR
Intervention: Short screw group (SSG) with 8 mm TJD
Number of subjects: 20
Study: 28424081

Group type: EXPERIMENTAL
Intervention: Increased vegetable portion sizes (150 g instead of 75 g) and decreased meat portion sizes (average reduction of 12.5%) during the intervention period.
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Control condition with usual portion sizes of main dishes.
Number of subjects: 1006

Group type: EXPERIMENTAL
Intervention: Increased vegetable portion sizes and decreased meat portion sizes during the intervention period.
Number of subjects: 1006
Study: 26084341

Group type: EXPERIMENTAL
Intervention: Insulin glargine 300 units/mL (Gla‐300)
Number of subjects: 549

Group type: COMPARATOR
Intervention: Insulin glargine 100 units/mL (Gla‐100)
Number of subjects: 549
Study: 25247740

Group type: EXPERIMENTAL
Intervention: Kangaroo Care (KC)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Auditory-Tactile-Visual-Vestibular (ATVV)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Any intervention (including KC and ATVV)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Control group (attention control)
Number of subjects: 240
Study: 22938664

Group type: EXPERIMENTAL
Intervention: Insulin glargine and regular insulin injection (experiment group)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Subcutaneous regular insulin injection (control group)
Number of subjects: 87
Study: 19283567

Group type: EXPERIMENTAL
Intervention: Pharmacologic treatment (psychoactive medication)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Non-pharmacologic treatment approaches
Number of subjects: 111
Study: 17602983

Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Beta-blocker therapy (general)
Number of subjects: 52
Study: 15220671

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus plantarum LP 01 and Bifidobacterium breve BR 03)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus plantarum LP 01 and Lactobacillus acidophilus LA 02)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (starch powder)
Number of subjects: 70